9-valent cervical cancer vaccine vaccination age

The 9-valent cervical cancer vaccine is suitable for women aged 16-26. The vaccine is mainly used to prevent human papillomavirus 16, 18, 31, 33, 45, 52, 58 infections and related cervical cancer, vulvar cancer, vaginal cancer and other diseases.

The vaccination age range of the 9-valent cervical cancer vaccine is based on clinical trial data. The immune response produced by women aged 16-26 after vaccination is better, and the antibody level can reach the expected protection standard. The vaccine has shown high safety and effectiveness in post-pubertal females. Common adverse reactions after vaccination are mostly minor reactions such as local redness and swelling, low-grade fever. People over 26 years old are not included in the routine vaccination scope because their immune response may be weakened, and most of them have a history of sexual life, which increases the risk of potential infection. For women over 26 years old, you can consider choosing the quadrivalent or bivalent cervical cancer vaccine for vaccination. The vaccine needs to be injected in three doses, with the full course of vaccination completed at 0, 2 and 6 months respectively. There is no need to conduct HPV testing before vaccination, but contraindications such as pregnancy and acute infection period need to be excluded.

It is recommended that women of appropriate age receive the 9-valent cervical cancer vaccine as early as possible if there are no contraindications, and undergo regular cervical cancer screening. After vaccination, you still need to maintain a healthy lifestyle and avoid high-risk behaviors such as multiple sexual partners. If there is an unexpected pregnancy during vaccination, subsequent doses should be suspended and the remaining vaccinations should be completed after delivery. Vaccination cannot replace routine cervical cancer screening. Women over 30 years old should undergo HPV testing combined with cytology every 3-5 years.